CTOs on the Move

G1 Therapeutics

www.g1therapeutics.com

 
G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company`s pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted ...
  • Number of Employees: 100-250
  • Annual Revenue: $500M-1 Billion
  • www.g1therapeutics.com
  • 79 T.W. Alexander Drive 4501 Research Commons Suite 100
    Research Triangle Park, NC USA 27709
  • Phone: 919.213.9835

Executives

Name Title Contact Details
David Elks
 Head of Information Technology Profile

Similar Companies

OmniAb

OmniAb is a leading edge antibody discovery company that provides access to diverse antibody repertoires and high throughput screening technologies. They specialize in therapeutic antibody discovery using chickens as immunization hosts, which allows fo...

Sheffield Bio-Science

Sheffield Bio-Science is a Norwich, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pervasis Therapeutics Inc

Pervasis Therapeutics Inc is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Civetta Therapeutics

Civetta Therapeutics was founded by William Sellers (Broad Institute and Dana-Farber Cancer Institute) and Eric Fischer (Dana Farber Cancer Institute and Harvard Medical School) to advance new medicines through small molecule intervention targeting propeller domains with the goal of developing important therapeutics for cancer and other indications.

Hound Labs

Hound Labs combines science and technology in novel ways to improve health and wellness. The Company believes its ultra-sensitive and portable technologies will pave the way to practical and fair solutions for some of the leading public health and safety issues. In the coming month, Hound Labs will launch the HOUND® CANNABIS BREATHALYZER, which allows employers and law enforcement to identify recent cannabis in breath. Dr. Mike Lynn, an ER physician, reserve deputy sheriff, and former venture capitalist, founded Hound Labs in 2014.